Chicago—Controversy over the use of ezetimibe/simvastatin to prevent progression of atherosclerosis continues to grow.
At the American Academy of Cardiology's 57th Annual Scientific Session here in March, attendees packed the lecture hall to hear a detailed account of the ENHANCE (Effect of Ezetimibe Plus Simvastatin vs Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial, 2 months after the company released the study's major findings to the media rather than to the scientific community. After the presentation, a panel assembled by the academy to put the findings in perspective declared that the aggressively marketed drug combination should be used only as a last resort in treating patients to decrease their levels of low-density lipoprotein cholesterol (LDL-C).
Graphic Jump Location
There is currently no evidence that ezetimibe, which reduces levels of low-density lipoprotein cholesterol (above), improves clinical outcomes such as myocardial infarction or death.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, ecologic studies such as the Seven Countries Study16 suggested a strong...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.